Clinical trial · Observational
Global Burden Estimation of Human Papillomavirus (GLOBE-HPV)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a multi-country and multi-site project to estimate the point-prevalence of high-risk (HR) HPV genotype infections among representative samples of girls and women aged 9-50 years, and among specific sub-populations to estimate the incidence of persistent HPV infection among sexually active young women. The data to fulfill the objectives will be collected through a series of Cross-Sectional Surveys (CSS) and Longitudinal Studies (LS) in all 8 countries 3 South Asian countries including Bangladesh, Pakistan, Nepal and 5 sub-Saharan African countries including Sierra Leone, Tanzania, Ghana, Zambia and DR Congo. Qualitative sub-studies (QS) will be conducted in selected countries and populations following the CSS to further understand and unpack risk factors for HPV infection as well as to explore how gender-related dynamics including perceptions of gender norms and stigma, influence HPV burden and/or create barriers that shape girls/women access to and uptake of HPV prevention, screening, and treatment services. Specific study protocols and corresponding ethical applications for the qualitative sub-studies will be developed separately.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HPV Infection | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood Samples | Other | — | UNRESOLVED |
| Self-collected Vaginal Swab | Other | — | UNRESOLVED |
| Urine Sample Collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Cross-Sectional Survey
- description
- There are total 14 CSS groups among 8 participating countries: Bangladesh has 3 groups for CSS (urban CSS, rural CSS, displaced population CSS); Pakistan has 3 groups for CSS (urban CSS, rural CSS, commercial sex worker population CSS); Nepal has 1 nationally representative CSS; Sierra Leon has 1 rural CSS; Tanzania has 2 groups for CSS (pastoralists CSS, displaced population CSS); Ghana has 1 urban CSS; Zambia has 1 group for urban \& rural representative CSS; DR Congo has 2 groups for CSS (population representative sample for urban and rural CSS, displaced population CSS)
- interventionNames
- Other: Urine Sample Collection
- label
- Longitudinal Study
- description
- There are total 11 LS groups: Bangladesh has 2 LS groups (married women up to 25 years-old \& 26-35 years old); Sierra Leone has 2 LS groups (Young girls subject to child marriage/early pregnancy \& general population); Tanzania has 2 LS groups (fishing, mining/tuck stop community \& general population) Other 5 countries have 1 LS group in each country.
- interventionNames
- Other: Urine Sample Collection
- Other: Self-collected Vaginal Swab
- Other: Blood Samples
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 9 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: 1. 9 to 50 years old (for urban and rural CSSs) at the time of enrollment. 2. Resident in the selected community for at least the past 3 months (with the exception of pastoralists, refugees, and commercial sex workers). 3. Able to understand the purpose of the study and study procedures. 4. If aged 18 years or older or legally considered an emancipated minor, able and willing to provide consent to participate in the study including sample collection. 5. If aged \<18 years (and not considered an emancipated minor), supported in their participation by a parent or guardian who is able and willing to provide consent, and 6. If aged \<18 years (and not considered an emancipated minor), able and willing to provide assent to participate in the study. Exclusion Criteria: 1. Decline consent to participate any activity of the study. 2. A medical condition or other reason, not directly related to HPV infection or HPV-related diseases, in the opinion of the investigator, precludes enrolment in the study.
References
Publications (0)
Data not yet available